ERBB2 and breast cancer: However, there are still many challenges in Her2-positive BC, including resistance to HER2-targeted therapies, the development of brain metastases, the need to determine the optimal sequence of anti-Her2, and the need to identify biomarkers to improve patient outcomes and personalized care (7).